Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.50 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.50 |
| ▸ | GLS | O94925 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 2/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9055208 | 1.00 | ROCK2 (0.50) | ROCK2ROCK1MYLK4GLSLMNA | |
| SCHEMBL29357884 | 0.90 | ROCK1 (0.52) | ROCK2ROCK1MYLK4 | |
| SCHEMBL2721958 | 0.83 | LMNA (0.50) | GLSLMNAALDH1A1CRHBPCRHR2 | |
| SCHEMBL2049579 | 0.83 | ALDH1A1 (0.66) | LMNAALDH1A1CRHBPCRHR2HTT | |
| SCHEMBL21430159 | 0.82 | FFAR2 (0.56) | ROCK2LMNAALDH1A1SMN1; SMN2GABBR2 | |
| SCHEMBL20429512 | 0.82 | LTA4H (0.51) | ROCK2 | |
| SCHEMBL7504901 | 0.81 | LMNA (0.49) | LMNAALDH1A1CRHBPCRHR2HTT | |
| SCHEMBL29456754 | 0.80 | EPHX1 (0.61) | LMNACRHBPCRHR2 | |
| SCHEMBL528413 | 0.80 | CYP1A2 (0.56) | LMNAALDH1A1CRHBPCRHR2HTT | |
| SCHEMBL23320094 | 0.79 | ALDH1A1 (0.49) | GLSLMNAALDH1A1CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951059-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3053913-B1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170233381-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233381-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.